Literature DB >> 30734299

Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Johnson Q Tran1, Marcus O Muench1,2, John W Heitman1, Rachael P Jackman1,2.   

Abstract

BACKGROUND AND OBJECTIVES: Alloimmunization is common following transfusion with platelet-rich plasma (PRP) and can cause complications such as platelet refractoriness or transplant rejection. It has previously been shown that pathogen reduction of PRP with riboflavin and UV light (UV+R) can protect against alloimmunization in mice and induce partial tolerance to subsequent transfusions.
MATERIALS AND METHODS: Using B6 H2d congenic mice, this study evaluated the relative contributions of major histocompatibility complex (MHC) antigens and minor antigens to both the alloresponse to PRP transfusion and the partial tolerance induced by UV+R treatment.
RESULTS: Both total and MHC-specific alloantibody responses were highest when both MHC and minor antigens were mismatched, with lower alloantibody responses observed with MHC mismatch alone, demonstrating that allogeneic minor antigens can enhance the response to allogeneic MHC. There was a weak, but significant alloantibody response to minor antigens only. UV+R treatment protected against both major and minor antigen alloimmunization. Both allogeneic MHC and minor antigens primed an enhanced cytokine response ex vivo, though this was weaker with minor antigens, and both responses were blocked with UV+R treatment.
CONCLUSION: Allogeneic MHC is both necessary and sufficient to induce the partial tolerance associated with UV+R treatment.
© 2019 International Society of Blood Transfusion.

Entities:  

Keywords:  alloimmunization; major histocompatibility complex; minor antigens; pathogen reduction; tolerance

Mesh:

Substances:

Year:  2019        PMID: 30734299      PMCID: PMC6465144          DOI: 10.1111/vox.12756

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  40 in total

1.  Characterization of immunologic tolerance induced by transfusion of UV-B--irradiated allogeneic mononuclear leukocytes.

Authors:  K J Kao; E S Huang; S Donahue
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

2.  Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support.

Authors:  C Sanz; C Freire; I Alcorta; A Ordinas; A Pereira
Journal:  Transfusion       Date:  2001-06       Impact factor: 3.157

3.  Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments:a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test.

Authors:  M Kurz; P Knöbl; P Kalhs; H T Greinix; P Höcker; S Panzer
Journal:  Transfusion       Date:  2001-06       Impact factor: 3.157

Review 4.  Extracorporeal photochemotherapy--present and future.

Authors:  R Knobler
Journal:  Vox Sang       Date:  2000       Impact factor: 2.144

5.  Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates.

Authors:  Martin Karpinski; Denise Pochinco; Iga Dembinski; Willie Laidlaw; James Zacharias; Peter Nickerson
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

Review 6.  Extracorporeal photopheresis: a review.

Authors:  A Oliven; Y Shechter
Journal:  Blood Rev       Date:  2001-06       Impact factor: 8.250

7.  Platelet alloantibodies in transfused patients.

Authors:  V Kiefel; C König; H Kroll; S Santoso
Journal:  Transfusion       Date:  2001-06       Impact factor: 3.157

8.  Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.

Authors:  P A Pappalardo; A R Secord; P Quitevis; M D Haimowitz; D Goldfinger
Journal:  Transfusion       Date:  2001-08       Impact factor: 3.157

9.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

10.  The importance of immune gene variability (MHC) in evolutionary ecology and conservation.

Authors:  Simone Sommer
Journal:  Front Zool       Date:  2005-10-20       Impact factor: 3.172

View more
  3 in total

1.  Characterization of glycoprotein IIb/IIIa-specific alloantibodies induced by cross-strain platelet immunization in mice.

Authors:  Daniel W Bougie; Jessica Sutton; Richard H Aster
Journal:  Transfusion       Date:  2021-01-22       Impact factor: 3.157

2.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

3.  A small allelic variant in donor class I MHC is sufficient to induce alloantibodies following transfusion of standard or pathogen-reduced platelets in mice.

Authors:  Rachael P Jackman; John W Heitman; Marcus O Muench
Journal:  Vox Sang       Date:  2020-03-23       Impact factor: 2.144

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.